Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 40
Biopharm constitutes 16% of Novo Nordisk sales and a
strategy has been defined to return to growth
bDKK
6
5
4
3
2
1
0
NovoSevenⓇ and Norditropin®
account for 82% of Biopharm sales¹
Other biopharmaceuticals
Other haemophilia products
NorditropinⓇ
NovoSevenⓇ
'Return to Growth' strategy builds on organic,
non-organic and organisational initiatives
Return to
growth
in Biopharm
Drive in-market brands beyond
current plans and ensure
successful pipeline launches
Pursue licensing or acquisition of
complementary assets or
companies
Strengthen the organisation to
drive the Biopharm return to
growth agenda
Q3
2013
1 Reported sales for the first nine months of 2018
changing
diabetes
Q3
2018
novo nordiskView entire presentation